EVOLUTION AT MERCK - INVENTING FOR LIFE

LYNPARZA: SET FOR SUSTAINED CLASS LEADERSHIP MERCK INVENTING FOR LIFE • • ● • Lynparza has class leadership in the U.S., with ~60% of total PARPi prescriptions The only PARPi with 1L maintenance indication in ovarian cancer based on strong results from SOLO-1 POLO data represents new opportunity in gBRCAm pancreatic cancer patients Additional indications with monotherapy and combinations with KEYTRUDA to drive significant growth going forward Growth opportunities across multiple tumor types Pancreatic cancer Prostate cancer and more In collaboration with AstraZeneca Ovarian cancer Breast cancer # Frank Clyburn 24 21

View entire presentation